1. Novel Concepts in the Management of RCC

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. The abstract data should be considered preliminary until published in a peer-reviewed journal.

3. Introduction

4. Nivolumab

5. Nivolumab + Ipilimumab

6. Notes on CheckMate 214

7. What About Patients With Favorable Risk?

8. irAEs

9. Stopping Checkpoint Inhibition

10. Combining Targeted and Immunotherapy

11. IMmotion151

12. Ongoing Trials Using Combination Therapy

13. Monotherapy in the First Line

14. Look to the Future

15. Concluding Remarks

16. Abbreviations

17. Abbreviations (cont)